logo

Sab Biotherapeutics, Inc. (SABS)



Trade SABS now with
  Date
  Headline
3/2/2022 7:01:35 AM SAB Biotherapeutics: NIH Ends Phase 3 ACTIV-2 Trial Of SAB-185 For COVID-19 Due To Low Hospitalization
2/25/2022 6:26:58 AM SAB Biotherapeutics Announces Update To Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 For COVID-19
1/24/2022 6:08:33 AM SAB Biotherapeutics Reports Positive Clinical Results From NIH ACTIV-2 COVID Trial
12/16/2021 6:10:51 AM SAB Biotherapeutics Says SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
12/1/2021 7:38:36 AM SAB Biotherapeutics Announces SAB-176 Meets Primary Endpoint In Phase 2a Challenge Study